Neurodegenerative Disease Therapeutics Market to Reach US$ 28.78 Billion by 2033 as Demand for Advanced Neurological Treatments Accelerates

DataM Intelligence has released a new research report titled "Neurodegenerative Disease Therapeutics Market Size 2026". The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the global Neurodegenerative Disease Therapeutics Market.

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/neurodegenerative-disease-therapeutics-market?ram

The Global Neurodegenerative Disease Therapeutics Market reached US$ 12.52 Billion in 2024 and is expected to reach US$ 28.78 Billion by 2033, growing at a CAGR of 9.8% during the forecast period 2025-2033.

The market is experiencing significant growth due to the rising global prevalence of neurological disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS). Increasing aging populations, growing awareness regarding early diagnosis, and continuous advancements in precision medicine and biologics are further driving demand for innovative neurodegenerative therapeutics worldwide.

Industry participants are increasingly focusing on disease-modifying therapies, biomarker-driven treatment approaches, and advanced drug delivery technologies to improve long-term patient outcomes. Strategic investments in neuroimmunology research, gene therapies, and AI-assisted drug discovery are accelerating therapeutic innovation, while regulatory support and expanding clinical trial pipelines are creating strong commercial opportunities across both developed and emerging healthcare markets.

Key Industry Developments

United States:
✅ April 2026: AskBio announced that its Viralgen unit will supply commercial-scale gene therapy material for the REGENERATE-PD investigational Parkinson's disease trial, strengthening advanced neurodegenerative therapy manufacturing capabilities. The company also highlighted Japan's SAKIGAKE designation for ametefgene parvovec, accelerating global Parkinson's R&D collaboration.

✅ March 2026: Denali Therapeutics dosed the first patient in its Phase 1b trial of DNL628, an Alzheimer's therapy using Oligonucleotide TransportVehicleTM technology to improve blood-brain barrier penetration and tau protein reduction. The company also advanced multiple Parkinson's disease programs targeting LRRK2 and alpha-synuclein pathways.

✅ January 2026: Cognition Therapeutics expanded development of zervimesine for dementia with Lewy bodies and Alzheimer's disease, preparing registrational discussions with the FDA following encouraging neuropsychiatric study findings. The company also presented new mechanistic data at the AD/PDTM 2026 conference focused on neurodegenerative therapeutics innovation.

Japan:
✅ December 2025: BlueRock Therapeutics received Japan's Pioneering Regenerative Medical Product (SAKIGAKE) designation for bemdaneprocel, an investigational cell therapy for Parkinson's disease. The designation supports accelerated development and regulatory review of regenerative neurodegenerative treatments in Japan.

✅ November 2025: Sysmex Corporation advanced neurodegenerative disease diagnostics research focused on Alzheimer's biomarkers and disease progression monitoring technologies. The company emphasized innovations in precision measurement systems to support earlier therapeutic intervention and personalised neurology care.

✅ October 2025: JCR Pharmaceuticals expanded collaborations for blood-brain barrier delivery technologies targeting Alzheimer's disease therapeutics, leveraging its J-Brain Cargo® platform. The company's partnership initiatives aimed to enhance central nervous system drug penetration and improve efficacy of next-generation neurodegenerative therapies.

Strategic Acquisitions & Partnerships
✅ AbbVie - Partnership
(May, 2025)
AbbVie announced a collaboration and license option agreement with ADARx Pharmaceuticals to develop siRNA-based therapeutics across multiple therapeutic areas, including neuroscience and neurodegenerative diseases. The partnership expanded AbbVie's neuroscience pipeline and strengthened its RNA-based drug development strategy targeting central nervous system disorders.

✅ Biogen - Strategic Partnership
(May, 2025)
Biogen entered a strategic collaboration with City Therapeutics to develop RNA interference (RNAi)-based therapies for central nervous system and neurodegenerative diseases. The deal focused on advancing next-generation RNA therapeutics for neurological disorders using City Therapeutics' RNAi engineering platform and Biogen's neuroscience expertise.

Key Players:
AbbVie Inc. | Amneal Pharmaceuticals LLC. | Eisai Co., Ltd. | F. Hoffmann-La Roche Ltd | Merck KGaA | Novartis AG | Pfizer Inc. | Teva Pharmaceutical Industries Ltd. | Otsuka Pharmaceutical Co., Ltd. | Orion Corporation

Key Highlights: Top 5 Key Players in Neurodegenerative Disease Therapeutics Market 2026
-AbbVie Inc.: Advanced its neuroscience pipeline through the development of tavapadon, a once-daily dopamine receptor agonist for Parkinson's disease. The company recently submitted a New Drug Application (NDA) to the U.S. FDA following successful Phase III TEMPO trial results demonstrating improved motor symptom control in Parkinson's patients.

-Eisai Co., Ltd.: Strengthened its Alzheimer's disease leadership with the continued global expansion of LEQEMBI® (lecanemab), an anti-amyloid beta monoclonal antibody therapy. Eisai recently secured European Commission approval and expanded clinical data for long-term efficacy and subcutaneous maintenance dosing for early Alzheimer's disease treatment.

-F. Hoffmann-La Roche Ltd: Expanded its neurodegenerative disease portfolio through advancements in biomarker-driven neurology diagnostics and investigational therapies targeting Alzheimer's and Parkinson's disease pathways. Roche continues integrating precision medicine approaches with neurological drug development to improve disease-modifying treatment outcomes.

-Novartis AG: Focused on innovative neuroscience research with therapies targeting multiple sclerosis and neurodegenerative disorders. The company has accelerated investments in RNA-based therapeutics and neuroinflammation-focused drug candidates to strengthen its next-generation neurological treatment pipeline.

-Pfizer Inc.: Continued expanding research collaborations and neuroscience drug discovery programs focused on Alzheimer's disease and rare neurodegenerative disorders. Pfizer recently emphasized AI-enabled drug discovery and biomarker-driven therapeutic development to enhance precision treatment capabilities in neurology.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/neurodegenerative-disease-therapeutics-market?ram

Main Drivers and Trends Shaping the Future of the Neurodegenerative Disease Therapeutics Market
-Advancement in Disease-Modifying Therapies: Growing research in monoclonal antibodies, gene therapies, and neuroprotective drugs is transforming treatment approaches for Alzheimer's, Parkinson's, Huntington's disease, and ALS, with increasing focus on slowing disease progression rather than only symptom management.

-Rising Global Aging Population: Rapid growth in the elderly population and increasing prevalence of cognitive disorders are significantly expanding demand for long-term neurodegenerative disease treatment and supportive care solutions worldwide.

-Biomarker and Precision Medicine Innovation: Advances in neuroimaging, blood-based biomarkers, AI-assisted diagnostics, and precision medicine are enabling earlier disease detection and personalized therapeutic strategies, improving treatment effectiveness and clinical trial success rates.

-Investment and Regulatory Momentum: Strong pharmaceutical investment, strategic collaborations, accelerated FDA approvals, and orphan drug incentives are encouraging innovation in neurological therapeutics and expanding the global development pipeline.

-Market Challenges: High clinical trial failure rates, complex brain biology, expensive drug development processes, limited curative therapies, and reimbursement concerns continue to restrain broader market growth.

Regional Insights:
-North America: 48.53% (Largest share, driven by strong presence of leading pharmaceutical companies, high adoption of advanced neurodegenerative therapies, and increasing Alzheimer's and Parkinson's disease prevalence).

-Europe: 22.38% (Supported by favorable regulatory approvals, strong healthcare infrastructure, and increasing investments in neurological disease treatment research).

-Asia Pacific: 20.53% (Fastest-growing region, fueled by rapidly aging populations, rising neurological disorder cases, and expanding healthcare access in China, Japan, and India).

-Latin America & Middle East Africa: 8.56% (Emerging growth regions supported by improving healthcare infrastructure, rising disease awareness, and increasing investments in neurology care).

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=neurodegenerative-disease-therapeutics-market?ram

Market Segmentation Analysis:
-By Drug Class: Dopamine Agonists and Cholinesterase Inhibitors Lead Therapeutic Adoption
Dopamine agonists and decarboxylase inhibitors are widely prescribed for managing motor symptoms associated with Parkinson's disease, improving dopamine activity and patient mobility.
Cholinesterase inhibitors remain a cornerstone in Alzheimer's disease treatment by supporting cognitive function and slowing symptom progression in early-to-moderate stages.
Immunomodulators are gaining attention due to increasing research into neuroinflammation and disease-modifying therapies, while other drug classes include NMDA antagonists and combination therapies addressing multiple neurodegenerative conditions.

-By Disease Type: Alzheimer's and Parkinson's Diseases Dominate Demand
Alzheimer's disease represents the largest therapeutic focus due to rising global dementia prevalence and aging populations.
Parkinson's disease drives strong demand for long-term symptomatic treatments aimed at improving motor control and quality of life.
Amyotrophic lateral sclerosis (ALS), Huntington disease, and other rare neurodegenerative disorders continue to witness growing research investment for targeted therapies and orphan drug development.

-By Route of Administration: Oral Therapies Remain the Preferred Choice
Oral formulations dominate due to ease of administration, long-term patient compliance, and broad availability of tablets and capsules for chronic treatment.
Injectable therapies are increasingly utilized for biologics, advanced immunotherapies, and hospital-based neurodegenerative treatments requiring rapid or targeted delivery.
Transdermal delivery systems are gaining traction for continuous drug release, reduced gastrointestinal side effects, and improved convenience in Parkinson's disease management.

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTW

Contact:
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to provide swift and astute solutions to clients like you. We encompass a multitude of syndicated reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.